Intervention: 50 mg intravenous hydrocortisone in 5 mL normal saline six-hourly until haemodynamic stability achieved, with subsequent steroid tapering over eight days. Control group received 5 mL normal saline. Outcome: Primary outcome -28-day all-cause mortality. Secondary outcomes -ICU and hospital mortality; mean arterial pressure; vasopressor doses; shock reversal; vasopressor-free days; mechanical ventilation-free days; and renal replacement-free days (in a 28-day period). Occurrence of steroid-related side effects was also documented.
The study: Single centre, randomised, placebo-controlled, double-blind trial with intention-to-treat analysis. Conducted between April 2004-October 2007 in King Abdulaziz Medical City ICU, Saudi Arabia; a 21-bed mixed medical and surgical closed ICU. The trial was stopped for futility at interim analysis.
The study patients: Eligible: Patients aged ≥18 years with liver cirrhosis who presented with septic shock within 72 hours of the onset of hypotension. A total of 140 patients were assessed for eligibility. Included: Seventy-five patients; 39 patients assigned to the hydrocortisone group and 36 to the placebo group. Excluded: Sixty-five patients were judged not eligible; 58 did not meet inclusion criteria; seven refused or were unable to consent within the randomisation window.
Study methods:
After enrolment all patients underwent randomisation and a corticotropin stimulation test (250 µg corticotropin with baseline and six-hour cortisol measurements). The laboratory staff were blinded to treatment allocation. The treating physicians and study investigators were blinded to the corticotropin stimulation test results. In both groups haemodynamic support followed Rivers' goal-directed therapy protocol. The vasopressor of choice was noradrenaline and meropenem was the preferred antibiotic, unless otherwise indicated by cultures and clinical setting. All patients received H 2 receptor blockers or proton-pump inhibitors for stress ulcer prophylaxis. Intervention group: (n=39). Patients received 5 mL normal saline containing 50 mg hydrocortisone every six hours. The full dose was continued until shock resolution (mean arterial pressure (MAP) >65 mm Hg without vasopressors for 24 hours); the hydrocortisone six-hourly dose was then reduced by 1 mL (10 mg) every two days until discontinuation. The trial end-point occurred if MAP remained >65 mm Hg for 24 hours after discontinuation of the study drug without vasopressors. If hypotension recurred during tapering, hydrocortisone was restored to 50 mg. If hypotension occurred after the trial end-point was reached, hydrocortisone was used open label at the discretion of the treating physician. Placebo group: The placebo group underwent the same protocol as the intervention group using 5 mL normal saline as the study drug.
The evidence:
See Table 1. EBM questions:
Do the methods accurately allow testing of the hypothesis? Yes.
This is a single centre, placebo-controlled, double-blind study. It was analysed by intention-to-treat analysis. Based on estimated 28-day mortality of 90%, and estimated absolute risk reduction of 20%, a sample size of 75 was required in each arm (using a two-sided type I error of 5% and a power of 80% from a multitude of studies make the role of hydrocortisone in septic shock unclear. The authors suggest further "multicenter randomized controlled trials, possibly using lower doses of hydrocortisone and for a longer duration". 6. Did they make any recommendations based on the results and were they appropriate? Vasopressor-free days, mean (SD) 6.8 (7.9) 5.6 (8.9) 1.2 (-2.7 to 5.1)* 0.54
Other outcomes
Ventilation-free days, mean (SD) 6.7 (7.7) 8.1 (10.9) -1.4 (-5.8 to 2.9)* 0.51
Renal replacement therapy-free days, 6.7 (7.8) 6.4 (10.6) 0.2 (-4.0 to 4.5)* 0.92 mean (SD) ICU length-of-stay for ICU survivors, 9.2 (6.4) 9.6 (6.0) -0.4 (-5.4 to 4.5)* 0.86 days, mean (SD) 8. What level of evidence does this study represent? 1B. This is a double-blind single centre randomised controlled trial with 100% patient inclusion for analysis. 9. What grade of recommendation can I make on this result alone? A. This study demonstrates no mortality benefit with this specific steroid regimen in patients with septic shock. A significant increase in associated complications (GI bleeding and shock relapse) suggests that this steroid regimen should not be employed for patients with cirrhosis and septic shock. Further conclusions on the role of steroids in septic shock are not possible (see below). 10. What grade of recommendation can I make when this study is considered along with other available evidence? D. Annane et al reported a significant mortality benefit with hydrocortisone in septic shock. 1 However, the Corticosteroid Therapy of Septic Shock (CORTICUS) trial 2 suggested no improvement in 28-day mortality with steroids. With current evidence, it remains difficult to draw conclusions on the role of steroids in septic shock. The randomisation window in this study was 72 hours. Consequently, the possible benefit of a short randomisation window in the study by Annane (eight hours) compared with CORTICUS (72 hours) remains unclear. 11. Should I change my practice because of these results? No. See above. 12. Should I audit my current practice because of these results? No.
The study does not indicate specific audit.
